Most patients with Alzheimer's disease exhibit accumulation of amyloid-b peptide on leptomeningeal and cortical arterioles, or cerebral amyloid angiopathy, which is associated with impaired vascular reactivity and accelerated cognitive decline. Despite widespread recognition of the significance of vascular dysfunction in Alzheimer's disease aetiology and progression, much uncertainty still surrounds the mechanism underlying Alzheimer's disease vascular injury. Studies to date have focused on amyloid-binduced damage to capillaries and plaque-associated arterioles, without examining effects across the entire vascular bed. In the present study, we investigated the structural and functional impairment of the feeding arteriolar versus draining venular vessels in a transgenic murine Alzheimer's disease model, with a particular focus on the mural cell populations that dictate these vessels' contractility. Although amyloid-b deposition was restricted to arterioles, we found that vascular impairment extended to the venules, which showed significant depletion of their mural cell coverage by the mid-stage of Alzheimer's disease pathophysiology. These structural abnormalities were accompanied by an abolishment of the normal vascular network flow response to hypercapnia: this functional impairment was so severe as to result in hypercapnia-induced flow decreases in the arterioles. Further pharmacological depletion of mural cells using SU6668, a platelet-derived growth factor receptor-b antagonist, resulted in profound structural abnormalities of the cortical microvasculature, including vessel coiling and short-range looping, increased tortuosity of the venules but not of the arterioles, increased amyloid-b deposition on the arterioles, and further alterations of the microvascular network cerebral blood flow response to hypercapnia. Together, this work shows hitherto unrecognized structural alterations in penetrating venules, demonstrates their functional significance and sheds light on the complexity of the relationship between vascular network structure and function in Alzheimer's disease.
Introduction
Alzheimer's disease, the most common cause of dementia, is characterized by progressive decline in cognitive functions that correlate with pathological alterations including deposition of amyloid-b peptide-containing extracellular plaques, accumulation of intracellular neurofibrillary tangles, and neurodegeneration (Querfurth and LaFerla, 2010) . Concurrent with parenchymal pathology, Alzheimer's disease is associated with cerebrovascular changes, including gross alterations in vascular structure and morphology (Fischer et al., 1990) , disruption of the basement membrane and the bloodbrain barrier (Kalaria and Hedera, 1995) , impaired regulation of blood flow (Mazza et al., 2011) , and cerebral amyloid angiopathy, i.e. accumulation of amyloid-b peptide on arterial walls (Attems et al., 2008) . As many as 90% of all Alzheimer's disease cases are comorbid with cerebral amyloid angiopathy (Attems et al., 2008) . Findings from both clinical and animal models suggest that cerebrovascular impairments precede onset of neurodegeneration and worsen with increasing severity of dementia (Fischer et al., 1990; Kalaria and Hedera, 1995; Attems et al., 2008; Mazza et al., 2011) . Despite demonstrations of strong linkage in various reports, questions remain as to whether a causative relationship exists between cerebrovascular and cognitive deterioration.
Cerebral vessels are comprised of endothelial cells that are ensheathed by astrocytic endfeet and various types of mural cells that originate from mesenchymal stem cells (Winkler et al., 2011) . Veins, venules and capillaries are typically ensheathed by mural cells characterized by a stellate morphology with long cytoplasmic processes, whereas arteries and arterioles are ensheathed by smooth muscle cells that appear more striated and organized (Hamilton et al., 2001) . Mural cells are important for brain homeostasis: they are contractile and can thus regulate vessel tone and blood flow (Hamilton et al., 2001) in addition to having phagocytic properties (Bergers and Song, 2005) . Developmental studies using platelet-derived growth factor receptor beta (PDGFRB)-null mice showed that pericyte loss results in dysregulation of endothelial cell proliferation and compromise in vascular architecture (Lindahl et al., 1997; Hellströ m et al., 2001 ) suggesting a pericyte-endothelial cell signalling mechanism dependent on PDGF. With regard to Alzheimer's disease and vascular amyloid-b, postmortem examination of patients with Alzheimer's disease brains revealed significant loss of pericytes on capillaries and smooth muscle cells on arterioles compared to nonAlzheimer's disease controls (Kawai et al., 1993; Sengillo et al., 2013) . In vitro studies demonstrated that both pericytes and smooth muscle cells uptake amyloid-b peptides and are sensitive to amyloid-b-induced cytotoxicity (Verbeek et al., 2000) . Recent work crossing pericytedeficient Pdgfrb + /À mice with an Alzheimer's disease transgenic mouse model revealed that global loss of capillary mural cells from birth results in vascular abnormalities, which accelerate progression of amyloid-b accumulation on pial arteries, tau pathology, and cognitive decline (Sagare et al., 2013) . Loss of pericytes in development, as a result of Pdgfrb knockout, results in increased permeability of the blood-brain barrier and decreased capillary density as early as 1 month of age, making it difficult to ascertain a direct role of mural cells in evolution of neurodegeneration (Sagare et al., 2013) .
In patients and animal models of Alzheimer's disease, vascular amyloid-b is frequently found on arteries, but less so on veins and capillaries (Weller et al., 2009a) . Development of vascular amyloid-b may result from impaired degradation by mural cells and perivascular macrophages, both of which internalize vascular amyloid-b (Bergers and Song, 2005; Hawkes and McLaurin, 2009; Sagare et al., 2013) and/or impaired drainage of amyloidb-containing interstitial fluid along arteriolar walls (Weller et al., 2009b) . In contrast, recent work using several fluorescent tracers showed drainage of fluorescent amyloid-b peptides out of the brain interstitial fluid along veins (Iliff et al., 2012) . Moreover, results from Alzheimer's disease transgenic mice showed that during early disease stages, small aggregates of amyloid-b first appeared in veins, whereas typical cerebral amyloid angiopathy pathology i.e. build-up of amyloid-b aggregates along arterial walls did not appear until later stages of disease (Michaud et al., 2013) . Thus, the role of veins and venules and their ensheathing mural cells in Alzheimer's disease progression has been largely overlooked.
We have previously shown that age-dependent accumulation of cortical vascular amyloid-b in the TgCRND8 mouse model of Alzheimer's disease correlates with progressive changes in vascular structure including increased tortuosity and decreased calibre of cortical penetrating arterioles (Dorr et al., 2012) . We demonstrated functional impairments in cortical vessels of TgCRND8 mice including elongation and higher dispersion of the microvascular network transit times and decreased microvascular reactivity to hypercapnia (Dorr et al., 2012) . Spurred by these findings, we set out to investigate mechanisms involved in these vascular changes. We hypothesized that vascular amyloid-b accumulation impairs mural cell function leading to vascular function impairment. We examined structural and functional consequences of pharmacological depletion of mural cells using the PDGFRB antagonist SU6668. Particular emphasis was placed on examining differential responses to mural cell loss between cortical penetrating arterioles and venules with respect to vascular morphology, function and amyloid deposition. mice overexpress human Swedish (KM670/671NL) and Indiana (V717F) amyloid precursor protein mutations under control of hamster prion protein promoter and exhibit early onset amyloid-b peptide deposition and cognitive deficits (Chishti et al., 2001) . All experimental readouts were performed at 5 or 7 months of age. Twenty-three mice were used for immunochemical analyses and 38 mice were used for blood-brain barrier permeability studies. Forty-one mice underwent morphological in vivo two-photon fluorescent microscopy imaging, of which 22 were challenged with hypercapnia and thus used in bolus tracking. All protocols were carried out in accordance with guidelines set by Canadian Council for Animal Care, University of Toronto, and Sunnybrook Research Institute.
SU6668 delivery
Sterile dimethyl sulphoxide (DMSO) or SU6668 (0.1 mg/ml in DMSO; A10953, Adooq) was prepared immediately before surgery and injected into lateral ventricles using Hamilton syringes at stereotaxic coordinates of + 0.75 mm posterior, + 1.25 mm right, and À2.5 mm ventral of bregma at 1 ml/ minute for total of 5 ml.
Immunofluorescence
Anaesthetized mice were transcardially perfused with phosphate-buffered saline (PBS) before extraction of brains. Extracted brains were post-fixed overnight in 4% paraformaldehyde (in PBS) at room temperature, washed three times with PBS, and embedded in 30% sucrose (in PBS) for 3 days at 4 C. Sucrose embedded brains were frozen and sectioned coronally at 40 mm/section. Floating sections were incubated in 10 mM sodium citrate (pH 6.0) for 30 min at 85 C to retrieve antigens. Heated sections were cooled at room temperature for 15 min, washed three times in PBS, and blocked in PBS containing 0.5% Triton TM and 5% normal donkey serum for 1 h. Probing of primary antibodies (Supplementary Table 1 ) (in 0.5% Triton and 5% normal donkey serum, at room temperature overnight) was followed by three PBS washes and simultaneous probing of fluorescence-conjugated secondary antibodies and tomato lectin (in 0.5% Triton TM and 5% normal donkey serum, at room temperature for 2 h). After three PBS washes, sections were stained with 1% filtered thioflavin S (in water) for 5 min, differentiated twice in 70% ethanol (5 min each), and washed three times in PBS before mounting.
Experimenters were blind to allocation of the animals to groups. Images of blood vessels in the somatosensory cortex were acquired using a TCS SP5 confocal microscope (Leica). Four evenly-spaced coronal sections between + 1.50 mm and À0.50 mm relative to bregma were scanned. Images were acquired along the pial surface of the somatosensory cortex. For each animal, 35-40 images containing at least one penetrating vessel were included for analysis. Penetrating vessels were defined as vessels that are 410 mm in diameter and run perpendicular to pial surface. The number of pixels in each fluorescent channel was summed after thresholding background/baseline pixel density to 7-10 pixels per 150 mm 2 .
Cortical blood vessel isolation and immunoblot
Cortical blood vessels were extracted from anaesthetized mice transcardially perfused with PBS, and cortices were dissected and frozen with dry ice. Mechanically homogenized cortices (in 0.1 M ammonium carbonate, 5 mM EDTA, 0.01% sodium azide, and 1% protease inhibitor cocktail (539134, Millipore) were centrifuged at 100 000g, (1h, 4 C). Pellets were resuspended in 0.1 M ammonium carbonate, 7% sodium dodecyl sulphate, and 2% protease inhibitor cocktail, stirred on ice for 4 h, and filtered through 40 -mm mesh filters to isolate blood vessel tufts from cortical filtrate. Isolated blood vessel tufts were sonicated in lysis buffer (10 mM Tris pH 8.0, 1 mM EDTA, 1 mM EGTA, 1% Triton TM , 0.1% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 140 mM NaCl, and 1% protease inhibitor cocktail) and centrifuged (17 000g, 15 min, 4 C). Supernatant was subjected to bicinchoninic acid protein assays (23225, Thermo) and electrophoresis. Before electrophoresis, samples were boiled in lithium dodecyl sulphate sample buffer (NP0007, Life Technologies) containing 1% b-mercaptoethanol. Boiled samples were electrophoresed in 12% bis-Tris gels (Life Technologies), and transferred to nitrocellulose membranes, which were blocked (1 h) in Tris-buffered saline-0.1% Tween (TBS-T) containing 10% milk, probed with a primary antibody solution (Supplementary Table 2 ) (in TBS-T containing 5% milk) overnight in cold room followed by horseradish peroxidase-conjugated secondary antibody solution (in TBS-T containing 5% milk, 1 h). ECL prime (RPN2232, GE Life Sciences) was used to develop membranes. Scanned protein bands were quantified using ImageJ and normalized to GAPDH.
Blood-brain barrier permeability
Sodium fluorescein (F6377 Sigma) and Evans Blue (46160 Sigma) were used to assess blood-brain barrier permeability (Nishitsuji et al., 2011; Rů žek et al., 2011) . Mice were injected intraperitoneally with either 10 mg sodium fluorescein or 2% Evans Blue dissolved in 100 ml of sterile PBS. As positive control, 20% mannitol (M9546 Sigma) was injected intravenously 30 min before. Cardiac blood was collected 45 min after sodium fluorescein/Evans Blue injections from right ventricle, and mice were transcardially perfused with PBS. Blood samples sat at room temperature for 1 h and centrifuged (17 000 g, 5 min, room temperature) to yield serum. Brains were removed, and cortices were dissected and mechanically homogenized in aforementioned lysis buffer and centrifuged (17 000 g, 15 min, 4 C). For sodium fluorescein measurements, after centrifugation proteins in supernatant were precipitated with 15% trichloroacetic acid at 1:10 supernatant:trichloroacetic acid. Serum samples were diluted 1:10 in PBS then 1:10 in 15% trichloroacetic acid. Acid-precipitated samples were incubated at 4 C overnight then centrifuged (17 000 g, 15 min, 4 C). Resulting supernatant was diluted 1:1 in 0.05 M sodium borate (pH 10.0). Fluorescein in each sample was measured using an Infinite M200 fluorescent plate reader (Tecan) at excitation 480 nm and emission 540 nm against known concentrations of sodium fluorescein. Total permeability of sodium fluorescein was expressed as ratio of brain sodium fluorescein to that in serum.
For Evans Blue measurements, serum samples were diluted 1:10 in PBS and used for normalization against centrifuged brain samples. Absorbance was measured at 630 nm against standard curve of known concentrations of Evans Blue. Total permeability of Evans Blue was expressed as the ratio of Evans Blue in brain to in serum.
Surgical preparation for in vivo imaging
Surgical procedures were similar to those detailed previously (Dorr et al., 2012) . Mice were anaesthetized with isoflurane (5% for induction; 1.5-2% for maintenance in oxygen enriched medical air, with 32% oxygen and balance nitrogen). To allow in situ two-photon fluorescence microscopy, we removed skull over a $3 mm diameter circular region centred at 1.5 mm medial-lateral and 0.5 mm anterior-posterior relative to bregma. Craniotomy was closed using a 5 mm circular glass coverslip, secured to the surrounding skull with cyanoacrylate adhesive. End-tidal respiratory pressure and end tidal CO 2 , transcutaneous CO 2 , temperature, oxygen saturation, breath and pulse distention and heart rate were recorded throughout surgery and imaging (Biopac MP150, Biopac Systems; MicroCapStar CO 2 monitor, CWE; TCM4, Radiometer; MouseOx, Starr Life Sciences).
Two-photon fluorescent microscopy Data acquisition
A tail vein catheter was implanted and fluorescent dextran (70 kDa Texas Red, 33 mg/kg, dissolved in PBS) administered intravenously. All imaging used a Â25, 1.05 NA, 2 mm working distance objective (Olympus). Imaging was performed using an FV1000MPE multiphoton laser scanning microscope (Olympus). Mai Tai Ti:Sapphire tunable laser (-1040 nm; Newport) was tuned to 900 nm to excite fluorescent dextran. An external photomultiplier tube (Hamamatsu) collected fluorescent emissions (570-620 nm).
To estimate microvascular transit times, which provide a measure of vascular reactivity and function, four bolus injections of fluorescent dextran (8.25 mg/kg each, total of 33 mg/ kg) were administered via tail vein catheter both during normocapnia and during hypercapnic challenge (7-10% CO 2 in inspired gas mixture), as described previously . Time series scans were acquired during each bolus at a single transverse plane at varying depths (256 Â 136 pixels matrix size, 2 mm/pixel, 2 ms/pixel, $ 230 ms/frame), for total scan time per bolus tracking acquisition of 60 s.
To image microvascular network morphology, a stack of slices parallel to cortical surface (with nominal in-plane resolution of 0.5-1.0 mm Â 0.5-1.0 mm) were acquired every 1.5 mm so as to span 300-600 mm of cortical depth, using dwell time of 4-8 ms/pixel, for total scan time of 10-45 min depending on imaging parameters and range of cortical depths imaged.
Bolus tracking data analysis
Bolus tracking analysis methods have been described in detail previously . Bolus time series data acquired during normocapnia and hypercapnia were 2D median filtered (3 Â 3 voxel kernel in x and y). Maximum intensity projection was performed on median filtered time series and vessels of interest segmented semi-automatically. Corresponding average vessel signal intensity time series were computed for every identified vessel and normalized to peak signal intensity. Bolus passage, during both normocapnia and hypercapnia, was next modelled using the gamma variate function (Kim et al., 2010; Kershaw et al., 2011) . Following our earlier work (Stefanovic et al., 2008) , the average vessel signal intensity changes with time were thus modelled as
where A is scaling constant, TTP is time to peak, FWHM is full-width at half-maximum, and t is time.
Morphological data analysis
Semi-automatic intensity-based segmentation of penetrating vessels was performed using Imaris (Bitplane). Given the plasmatic distribution of fluorescent dextran, diameter estimates on these vessels thus reflect to the intraluminal diameter of the vessels. As before, tortuosity was defined as the ratio of the distance along the vessel between beginning and endpoints normalized by the 3D Euclidian distance between the vessel endpoints (Bullitt et al., 2003) . The minimum tortuosity value, of 1, thus indicates a straight vessel, whereas larger tortuosity values indicate more curved vessels. The penetrating vessels were designated as arteries or veins based on their morphological features and branching pattern (Scharrer, 1940; Duvernoy et al., 1981; Kasischke et al., 2011) . In particular, those cortical penetrating vessels exhibiting few branches across the cortical depth, having a large capillary-free space in their surround and having a fairly constant diameter throughout their length were designated as arteries. Vessels showing more branches, a smaller capillary free space in their surround, and a diameter that increased toward the cortical surface were deemed venules. Vessel designation was validated using the resting-state bolus-tracking data since venules exhibit delayed bolus arrival times relative to the arterioles. Primary branches of the thus categorized penetrating vessels were then designated as either a venular branch or an arteriolar branch. Vessels 510 mm in diameter and not immediately connected to a penetrating vessel were designated as capillaries.
Statistical analysis
Quantifications for immunofluorescence and immunoblot were analysed for significance using either t-test or ANOVA followed by Newman-Keuls post hoc where multiple comparisons apply. Data for two-photon fluorescent microscopy were analysed as follows: to detect outliers, we computed modified zscores on the times to peak across different vessels within each of four cohorts, during both normo-and hypercapnia periods. Those observations whose modified z-score exceeded 3.5, as per Iglewicz and Hoaglin (1993) , were deemed outliers and removed from subsequent analysis. All data were analysed using linear mixed effects analysis (lme function in nlme package, R), with animals treated as random variables, thus allowing for within-animal errors to be correlated. This modelling yields sensible restricted maximum likelihood estimates from unbalanced allocation of animals by factor (Pinheiro and Bates, 2000) . For penetrating vessel morphology measurements, tortuosity and average radius were modelled as linear mixed effects functions of treatment (SU6668, DMSO) and vessel type (arteriole, venule) in both transgenic animals and non-transgenic littermates. For bolus tracking analysis, the time-to-peak during CO 2 breathing was modelled as linear function of the time-to-peak during air breathing, with subject and bolus repetition treated as nested random effects.
Results

Vascular amyloid deposits on arterioles while mural cells are lost from venules
Penetrating arterioles and venules transport blood between the pial surface and the parenchyma, and are critical for healthy cortical perfusion: they are thus particularly important targets in the study of vascular pathology (Shih et al., 2013) . We have previously shown, using thioflavin S staining, that in TgCRND8 mice maintained on a 129 background, amyloid-b peptide deposition on cortical penetrating arterioles increases dramatically during the transition from mid-stage to late-stage Alzheimer's disease-like pathology (previously defined as 7-12 months of age) (Dorr et al., 2012) . We now report changes in mural cell morphology and function in the cortical penetrating vessels of 7-month-old mice. To determine whether mural cells are affected in this model of Alzheimer's disease, we immunolabelled cortical sections with desmin and -smooth muscle actin (ACTA2, also known as alpha smooth muscle actin, A-SMA), both cytoskeletal proteins expressed by subpopulations of mural cells but not by other cell types (Hamilton et al., 2001; Hughes and Chan-Ling, 2004) . We identified two types of penetrating vessels in the cortex: the first being desmin + /ACTA2 + /cerebral amyloid angiopathy + and covered with mural cells of striated morphology representing arterioles (Fig. 1A) ; the second being desmin + /ACTA2 À / cerebral amyloid angiopathy-and covered with stellate mural cells representing venules (Fig. 1B) (Hamilton et al., 2001; Hughes and Chan-Ling, 2004 ). These two types of penetrating vessels can be further delineated using CD13 (now known as ANPEP) expression; we found that penetrating arterioles were ACTA2 + /ANPEP À whereas penetrating venules were ACTA2 À /ANPEP + (Fig. 1C) .
To ascertain a link between mural cell loss and vascular amyloid deposition, we measured the areas covered by desmin and/or thioflavin S in relation to the total vessel wall area. In 5-month-old mice, the penetrating arterioles of TgCRND8 mice have significantly higher thioflavin S coverage (14 AE 2%) compared to background thioflavin S coverage (4 AE 0%) in non-transgenic littermates (P = 0.0004) (Fig. 2A) . In 7-month-old mice, thioflavin S coverage in the penetrating arterioles of TgCRND8 mice increased further to 23 AE 3% compared to 5 AE 2% in non-transgenic littermates (P = 3 Â 10 À5 ) (Fig. 2B) . In contrast, penetrating venules in both TgCRND8 and nontransgenic littermates had neglible levels of thioflavin S coverage regardless of age (5-month-old: 4 AE 0% and 5 AE 1%, respectively; 7-month-old: 5 AE 2% and 4 AE 1%, respectively) ( Fig. 2A and B) . Surprisingly, increased thioflavin S coverage in the penetrating arterioles of TgCRND8 mice was not accompanied by changes in their mural cell coverage as shown by desmin labelling ( Fig. 2) : there were no alterations in desmin coverage in either penetrating arterioles or venules of 5-month-old TgCRND8 mice (Fig. 2C) . However, in 7-month-old TgCRND8 mice, a significant decrease in mural cell coverage was unexpectedly observed in penetrating venules (74 AE 7% coverage in nontransgenic versus 54 AE 4% coverage in TgCRND8; P = 0.0076) with no significant alterations of mural cell coverage of penetrating arterioles (P = 0.5328; Fig. 2D ).
Immunoblot analysis of cortical vessel-enriched preparations corroborated the above findings. In cortical vessels isolated from 7-month-old TgCRND8 mice, we observed a pronounced loss of desmin expression compared to nontransgenic littermates (P = 0.0361) concurrent with a trend for decreased expression of NG2 (now known as CSPG4/NG2) (P = 0.0756) (Fig. 3A-C) , a chondroitin sulphate proteoglycan expressed by differentiated pericytes but absent in smooth muscle cells (Hughes and Chan-Ling, 2004) . In contrast, ACTA2 protein levels in cortical vessel preparations were not significantly different between TgCRND8 and non-transgenic littermates (P = 0.9682) (Fig. 3A and D) . Contrary to previous findings, our combined results demonstrate significant mid-stage damage to the venules.
SU6668-induced depletion of mural cells on penetrating vessels exacerbates arteriolar amyloid accumulation
We next investigated the effects of mural cell depletion on vascular amyloid accumulation and vascular function in penetrating arterioles and penetrating venules. At the concentrations used here, the compound SU6668 exhibits specific antagonist activity for PDGFRB over other structurally similar receptors and has been previously shown to inhibit proliferation of activated pericytes in tumours (Bergers et al., 2009) . PDGFRB is expressed by all mural cells and mediates signalling crucial for survival and function of these cells (Lindahl et al., 1997) . Here, we found that intracerebroventricular delivery of SU6668 to TgCRND8 mice resulted in a dose-dependent loss of mural cell coverage on penetrating venules with the most effective dose, of 0.5 mg, reducing coverage from 54 AE 4% (in vehicle-treated TgCRND8 mice) to 40 AE 2% (P = 6Á Â 10 À4 ) (Figs 2D and 4). As mural cell loss was comparable between 7 and 14 days post-injection (Fig. 4) , we performed all subsequent experiments 14 days post-injection to characterize the new steady-state. SU6668 treatment also induced mural cell loss in penetrating arterioles, from 71 AE 4% coverage (in vehicle-treated TgCRND8 mice) to 59 AE 3% coverage in SU6668-treated TgCRND8 mice (P = 0.0029) (Fig. 2D) . Corroboratively, immunoblot analysis of cortical vessel preparations showed that SU6668 treatment resulted in a significant reduction of desmin expression (relative to vehicle-treated TgCRND8 mice; P = 0.0276) as well as CSPG4/NG2 expression (relative to non-transgenic littermates; P = 0.039) (Fig. 3A-C) . Concomittantly, PDGFRB expression increased in response to SU6668 treatment (P = 0.01 relative to non-transgenic littermates), which is indicative of a compensatory response against loss of PDGFRB signalling (Fig. 3A and E) . Despite the loss of mural cells on penetrating arterioles, immunoblot showed that SU6668 treatment did not affect ACTA2 expression globally ( Fig. 3A and D) . Nonetheless, quantification of ACTA2 coverage on penetrating arterioles showed an SU6668-induced loss of mural cells similar in magnitude to that observed via desmin staining (52 AE 5% in vehicle versus 42 AE 5% in SU6668-treated mice, P = 0.0505) (Supplementary Fig. 1A) . Notably, neither CD206 (now known as MRC1) nor GLUT1 (now known as SLC2A1), markers of perivascular macrophages and endothelial cells, respectively, showed altered protein levels after SU6668 treatment, in support of the treatment's specificity (Fig. 3A, F and G) . Coverage of CD206-positive perivascular macrophages on both penetrating arterioles and venules was also unaffected by SU6668 treatment ( Supplementary  Fig. 1 B) .
Mural cell loss on the penetrating vessels induced several alterations in the cortical vasculature. SU6668-treated TgCRND8 mice exhibited exacerbated arteriolar amyloid accumulation with a thioflavin S coverage of 34 AE 4% compared to 23 AE 3% in vehicle-treated TgCRND8 mice (P = 0.0061) (Fig. 2B) . Expression of aquaporin 4 (AQP4) and S100B, both astrocytic indicators of blood-brain barrier integrity alterations (Kanner et al., 2006; Wilcock et al., 2009) , were markedly increased by SU6668 treatment (P = 0.0403 for AQP4; P = 0.0412 for S100B) (Fig. 3A, H and I) . To probe for any effects on the blood-brain barrier integrity, we measured the amount of peripherally-injected sodium fluorescein and Evans Blue that crossed the blood-brain barrier. We found that SU6668 treatment did not significantly alter blood-brain barrier permeability to either sodium fluorescein (P = 0.4566) or Evans Blue (P = 0.1885) (Fig. 5) , suggesting that the observed changes in AQP4 and S100B levels were compensatory mechanisms relating to blood-brain barrier stabilization following loss of mural cells.
In contrast to TgCRND8 mice, non-transgenic littermates treated with SU6668 did not exhibit loss of mural cell coverage in either penetrating arterioles or penetrating venules ( Supplementary Fig. 2A ). Protein levels of mural cell markers desmin, PDGFRB, and ACTA2 were also unchanged in SU6668-treated non-transgenic compared to DMSO-treated non-transgenic littermates ( Supplementary  Fig. 2 B-F) . Interestingly, despite no apparent loss of mural cells, SU6668 treatment decreased protein expression of CSPG4/NG2, which has been previously shown to be downregulated in quiescent vasculature ( Supplementary  Fig. 2B and D) (Ozerdem et al., 2001) .
SU6668 treatment leads to in vivo vascular morphology abnormalities
Visual inspection of the two-photon fluorescent microscopy data acquired showed numerous instances of increased tortuosity of the cortical penetrating arterioles in the TgCRND8 mice, as we reported previously (Dorr et al., Figure 2 Quantification of cerebral amyloid angiopathy and mural cell coverage on penetrating vessels. Mural cell loss on venules (v) correlates with increased arteriolar (a) cerebral amyloid angiopathy (CAA). Coverage of cerebral amyloid angiopathy and mural cells was quantified in vehicle-treated non-transgenic (nTg) littermates, vehicle-treated TgCRND8, and SU6668-treated TgCRND8 mice. ANOVA followed by Newman-Keuls post hoc was used to measure statistical significance where *P 5 0.05. (A and B) Quantification of cerebral amyloid angiopathy coverage in (A) 5-month-old and (B) 7-month-old mice measured by the number of thioflavin S (thioS) pixels over the number of lectin pixels in a penetrating vessel. n = 5 for all treatment conditions. (C and D) Quantification of mural cell coverage in (C) 5-month-old and (D) 7-month-old mice measured by the number of desmin pixels over the number of lectin pixels. n = 4 for vehicle-treated non-transgenic mice. n = 6 for vehicle-treated TgCRND8 and SU6668-terated TgCRND8 mice. 2012). Further, profound aberrations in the cortical microvascular morphology in the SU66668-treated TgCRND8 mice were observed, including vessel coiling and shortrange looping (Fig. 6A-C) . In vivo morphological examinations of the cortical penetrating vessels revealed increased tortuosity of the venules (P = 0.0094)-but not arterioles (P = 0.94)-on SU6668 treatment ( Fig. 6D and E) across all animals: venular curvature trended toward increase in transgenic (P = 0.16) and increase in non-transgenic animals (P = 0.035). Moreover, the SU6668 treatment was associated with decreased arteriolar calibre (P = 0.052) in the transgenic, but not in the non-transgenic animals (P = 0.32), in support of the cerebral amyloid angiopathydependent effect of SU6668 on the arteriolar bed, i.e. with increased cerebral amyloid angiopathy (secondary to SU6668 treatment) leading to decreased arteriolar calibres. Combined, these results suggest that the structural changes in venules are driven by loss of mural cells, whereas arteriolar morphology changes are dependent on arteriolar amyloid accumulation.
SU6668 treatment leads to in vivo vascular dysfunction
To examine the functional consequences of the morphological changes in the TgCRND8 vasculature with and without SU6668 treatment, we quantified the microvascular perfusion by imaging the passage of a fluorescent bolus through the microvascular bed, as described in detail previously (Dorr et al., 2012) . Changes in cerebral blood flow elicited by hypercapnia were assessed based on the timing of peak signal enhancement in individual vessels following peripheral intravascular injection of a fluorescent contrast agent. The change in blood flow was computed from relative vessel-wise dispersion of these signal peaks under each condition. Figure 6F and G thus shows the scatter plots to the times-to-peak of the intravascular fluorescence across all vessels (total of 925) during hypercapnia versus those during air breathing, for TgCRND8 (Fig. 6F ) and nontransgenic (Fig. 6G ) mice, along with the corresponding regression lines. The hypercapnia-induced flow changes, estimated as the inverse of the regression slope, are listed in Table 1 for each of the four cohorts.
SU6668 treatment uniformly attenuates vascular reactivity to hypercapnia in non-transgenic mice
Non-transgenic littermates exhibited uniform amplitude of hypercapnia-induced flow response across the different vessel types (arterioles/capillary/venules) of the microvascular network (P = 0.8 on the effect of vessel type on hypercapnia-induced flow change). SU6668 treatment significantly attenuated the non-transgenic response to hypercapnia (P = 10 À5 ), from a CO 2 -induced flow increase by a factor of 2.4 AE 0.1 in untreated non-transgenic to a flow increase by a factor of 1.2 AE 0.1 in SU6668-treated mice. As with DMSO-treated non-transgenic littermates, SU6668-treated non-transgenic littermates' response to hypercapnia did not vary across the different vessels (P = 0.4). These results are consistent with interruption of mural cell-endothelial cell cross talk under normal physiological conditions, i.e. in the absence of Alzheimer's disease pathology.
SU6668 treatment partially restores venular reactivity to hypercapnia in TgCRND8 mice
As demonstrated in our earlier work, TgCRND8 mice had an attenuated flow response to hypercapnia relative to nontransgenic littermates (P = 10 À5 ). Unlike non-transgenic littermates, TgCRND8 mice exhibited a trend toward lower flow responses to hypercapnia in arterioles relative to capillary/venular vessels (P = 0.1), consistent with preferential cerebral amyloid angiopathy deposition on the arteriolar walls and the likely consequential drop in compliance. SU6668 had a significant effect on TgCRND8 vessels' response to hypercapnia (P = 0.002). In contrast to nontransgenic littermates, the flow response of TgCRND8 vessels to hypercapnia was increased by SU6668 treatment (P = 10 À5 ), from essentially no change due to hypercapnia under vehicle treatment (flow increase factor of 1.1 AE 0.1) to a flow increase by a factor of 1.7 AE 0.2 under SU6668 treatment. We next contrasted the responses of arteriolar and non-arteriolar (i.e. venular/capillary) vessels. Under vehicle treatment, TgCRND8 arterioles showed a small decrease in flow with hypercapnia (0.8 AE 0.2; P = 10 À5 ); under SU6668, arterioles started showing an increase, albeit highly variable, by a factor of 1.6 AE 0.4 (P = 10 -5
). The venules/capillaries flow remained largely unchanged due to hypercapnia (factor of 1.1 AE 0.2) under vehicle treatment (P = 10 À5 ); following SU6668 treatment, however, hypercapnia elicited a large increase in non-arteriolar vessels flow by a factor of 2.1 AE 0.3 (P = 10
À5
). These results suggest a partial mitigation of vascular dysfunction by SU6668 treatment, predominantly mediated by the relative improvement in venular reactivity.
Discussion
Although mural cell absence has been shown to partly account for the irregular, tortuous, and leaky blood vessels found within tumours (Morikawa et al., 2002; Abramsson et al., 2003) , the role of mural cells in vascular injury in Alzheimer's disease is largely unknown. Moreover, it is unclear whether the Alzheimer's disease-specific pathology gives rise to vascular network deficits directly and how much of the vascular compromise is due to arteriolar versus venular dysfunction. The present study shows that loss of mural cells on cortical penetrating venules, but not arterioles, is a direct result of Alzheimer's disease-like changes within the CNS as TgCRND8 mice have decreased number of mural cells in comparison to non-transgenic littermates. We further demonstrate that this SU6668-induced selective loss of mural cells around venules does not affect macrophage, endothelial or astrocyte cell numbers, nor increase blood-brain barrier permeability.
We have defined mural cells as vascular ensheathing smooth muscle cells and pericytes that regulate Mural cell coverage is compared between non-injected non-transgenic littermates, DMSO-injected TgCRND8 mice, and SU6668-injected TgCRND8 mice (0.1 mg to 50 mg). Coverage is expressed as the number of desmin pixels over the number of lectin pixels. n = 3 for all treatment conditions. ANOVA followed by Newman-Keuls post hoc was used to measure statistical significance where # P 5 0.05 relative to vehicle-treated non-transgenic (nTg) littermates and *P 5 0.05 relative to vehicletreated TgCRND8 mice. (A) Seven days after SU6668 delivery; and (B) 14 days after SU6668 delivery.
angiogenesis and vessel contractility with some capacity for phagocytosis (Bergers and Song, 2005) . Perivascular macrophages, though similar in developmental origin, ensheath the vessels less extensively and serve primarily as responders of insult including amyloid-b peptide (Hawkes and McLaurin, 2009) . Despite the integrity of perivascular macrophages and other components of the vasculature, the results of pharmacologically-induced loss of mural cell population clearly demonstrate that their depletion has consequences for vascular network state. In particular, exacerbation of mural cell loss using SU6668 treatment, illustrated by a further loss of desmin and CSPG4/NG2 protein levels, leads to greater structural alterations in venules and increased vascular amyloid on arterioles. Immune functions mediated by mural cells, including facilitation of neutrophil infiltration into the brain (Pieper et al., 2013) and activation of primed lymphocytes (Balabanov et al., 1999) , has not been demonstrated to date in the TgCRND8 brain. However, PDGFRB antagonism induced mural cell detachment from the vascular wall and mural cell loss, thus likely affects many physiological functions of the mural cells. We observe a concomitant increase in the protein levels of astrocytic S100B and AQP4, both of which are associated with increasing cerebral amyloid angiopathy (Wilcock et al., 2009; Yang et al., 2012) , despite preserved vessel wall integrity as evidenced by the lack of permeability to exogenously applied dyes. A closer examination at the cellular localization of AQP4, as well as other membrane proteins such as PDGFB, may elucidate more aspects of protein functionality than measuring levels of expression alone. Nevertheless, the collective data suggest that amyloid-b accumulation and toxicity within the CNS involves slowly evolving damage to the vasculature starting with the most vulnerable of the vasculature-associated cells, the mural cells (Fischer et al., 1990; Kalaria and Hedera, 1995; Sengillo et al., 2013) . Current literature supports the notion that solute drainage from the brain relies on both perivascular and lymphatic pathways, whereby solutes transported by glia and collected into the perivascular space exit at cervical lymph nodes (Iliff et al., 2012; Carare et al., 2014) . In light of morphological and functional changes in the vasculature and increased vascular amyloid accumulation, we expect both draining routes to be affected by both the disease process and the current pharmacological intervention and thus contribute to amyloid-b accumulation.
In accordance with the established role of mural cells in affording structural support and imbuing the microvasculature with contractile capacity, we found significant changes in both microvascular morphology and function upon treatment with SU6668. In light of low levels of activated mural cells under physiological conditions, we believe that SU6668 treatment caused antagonism at the mural cell PDGFRB leading to downregulation of the CSPG4/NG2 protein, rather than frank depletion of mural cells in the non-transgenic littermates. Mural cell CSPG4/NG2 is an important regulator of the cross-talk with endothelial cells that is believed necessary for structural integrity of blood vessels (Ozerdem et al., 2001) . Consistent with this notion, the SU6668-treated non-transgenic littermates exhibited attenuated flow increases to the vasodilatory CO 2 challenge. On the other hand, due to the high level of activated mural cells in the transgenic mice, we believe SU6668 treatment produced true depletion of mural cells in the transgenic animals. Consequently, SU6668 treatment compromised the compliance of the capillary/venular vessels, thus effectively producing a rebalancing of the relative vascular wall compliance between arteriolar and venular/ capillary compartments. It is this rebalancing of the relative compliance across the microvascular network that we believe explains the paradoxical improvement in flow responses to hypercapnia in SU6668-treated TgCRND8 animals. Importantly, despite the relative improvement of the microvascular reactivity to CO 2 in SU6668-treated Figure 5 Mural cell depletion does not affect blood-brain barrier permeability. Blood-brain barrier permeability to (A) sodium fluorescein and (B) Evans Blue in vehicle-treated (n = 4) and mannitol-treated non-transgenic mice (n = 5) and vehicle-treated TgCRND8 (n = 5) and SU6668-treated TgCRND8 mice (n = 5). Blood-brain barrier permeability is expressed as ratio of sodium fluorescein/Evans Blue in the cortical homogenate compared to that in the serum 45 min after intraperitoneal injection.
versus vehicle-treated transgenic mice, the hypercapnic response measured in the SU6668-treated TgCRND8 animals was still compromised: i.e. it was still attenuated relative to that measured in the vehicle-treated non-transgenic littermates.
There is mounting evidence that the cerebrovascular reactivity to hypercapnia is attenuated in patients with Alzheimer's disease and mild cognitive impairment (Oishi et al., 1999; Vicenzini et al., 2007; Glodzik et al., 2011; Yezhuvath et al., 2012) : the reported magnitude of this compromise has been variable, largely due to the technical challenges in quantifying cerebrovascular reactivity to CO 2 at high spatial resolution non-invasively (Glodzik et al., 2013) . Notwithstanding, regional hypercapnia-induced hyperaemic response attenuation by as much as 50% has been reported (Yezhuvath et al., 2012) as have hyperacapnia-elicited cortical blood flow decreases in some patients (Glodzik et al., 2011) . The range of this attenuation is thus A and B) , loops (blue arrow in B), and meandering vessels (yellow arrows in C). Scale bar = 50 mm. (D and E) Segmentation of cortical penetrating vessels overlaid on maximum intensity projections of cortical microvasculature in the TgCRND8 mice treated with DMSO (D) and with SU6668 (E). Penetrating arterioles are highlighted in red and penetrating venules in blue. Average tortuosity of penetrating venules for each sample subject (mean AE standard error): DMSO-treated transgenic (TgCRND8 + DMSO) 1.030 AE 0.005 and SU6668-treated transgenic (TgCRND8 + SU6668) 1.065 AE 0.016. Scale bar = 200 mm. (F and G) The time-to-peak of the intravascular fluorescence signal during hypercapnia versus that during air breathing across all imaged vessels in DMSO-treated (red) and SU6668-treated (green) animals. Superimposed are the regression lines to these data, with 95% confidence interval on the fit shown as the shaded region. Flow response to hypercapnia was estimated by the inverse slope of the regression lines: a slope of 1 thus indicates no change in flow with hypercapnia whereas progressively smaller slopes indicate larger hypercapnia-elicited increases in flow. In the non-transgenic littermates (F), SU6668 resulted in attenuation of the hypercapnia-induced flow increase. In contrast, in TgCRND8 animals (G), SU6668 treatment resulted in partial restoration of the hypercapnia-induced flow response. The parameter estimates along with fit quality metrics for these fits are listed in Table 1 . recapitulated in our studies using the TgCRND8 murine Alzheimer's disease model. Dysregulation of vascular reactivity is a useful clinical readout because it strongly correlates with hypoperfusion in Alzheimer's disease. The mechanisms underlying the vasodilatory response to hypercapnia are unclear. In Alzheimer's disease, endothelin-1 production, cholinergic signalling, inflammatory mediators, and anatomical vascular alterations have been suggested as contributors (Glodzik et al., 2013) . Here, the decoupling of the tightly regulated signalling and anatomical interaction between mural cells and the endothelium is likely to play a major role. Degeneration of mural cells, observed in the current study as well as in patients with Alzheimer's disease (Sengillo et al., 2013) , may explain the similar responses to hypercapnia in TgCRND8 mice and patients with Alzheimer's disease.
To our knowledge, results from the current study are the first to compare cortical penetrating venules versus penetrating arterioles with respect to mural cell degeneration and cerebral amyloid angiopathy development. There are however other findings from both rodent and human studies that corroborate our data. White matter hyperintensities commonly observed in patients with Alzheimer's disease coincide with both arteriolar tortuosities and venular occlusions caused by collagenosis (Black et al., 2009) . Notably, pathological replacement of the vascular mural cells by collagen is specific to venules and excludes arterioles and capillaries (Moody et al., 1997) . Retinal vessels of patients with Alzheimer's disease also exhibit venule-specific aberrations including decreased venular calibre and venule-to-arteriole ratio (Frost et al., 2013) . Sengillo et al. (2013) reported loss of pericytes in the CNS capillaries of patients with Alzheimer's disease but did not examine the venules. These pathological findings are end-stage disease but are consistent with both venular and arteriolar degeneration.
On the whole, these data indicate the importance of studying the microvascular morphology and function across the different compartments of the microvascular network and shed light on the presently underappreciated role played by the draining vasculature in overall vascular reactivity in Alzheimer's disease. We demonstrate that microvascular compromise extends beyond the deposition of the vascular amyloid on the arteriolar vessels and includes mural cell loss on the venular vessels. We provide direct evidence of the significance of the mural cell depletion for the microvascular network function, thus identifying a new target for interventions aimed at normalizing vascular injury in Alzheimer's disease. 
